Started running in 2018 - 5k, 10k, half marathons and a marathon later - things I never thought I’d be able to do and perhaps an Ultra next. Give running a try 🏃🏻‍♀️#GlobalRunningDay

Long term NHS workforce plan for England published at last after several months of delays. bbc.co.uk/news/health-66…

Absolutely heartbreaking news 💔 Nicola was an incredible campaigner and we loved working with her on the Trodelvy campaign. Sending all our love and thoughts to her family

Amazing to be at the stadium for this

Today trastuzumab deruxtecan (Enhertu) has been provisionally rejected for use on the NHS in England for certain patients with HER2-low secondary breast cancer. NICE and the drug company Daiichi Sankyo must urgently work together to find a solution...

"Give us hope for the future.” We’re sharing an open letter from 6 women with HER2-low incurable secondary breast cancer: NICE, Daiichi Sankyo UK and NHS England work together so trastuzumab deruxtecan (Enhertu) is available on the NHS in England. breastcancernow.org/enhertuopenlet…

News that the license for anastrozole be extended to cover its use as a risk-reducing treatment for breast cancer is a step forward that ‘paves the way’ for more eligible women with a significant family history of breast cancer to reduce their chance of developing the disease.

Kevin Sinfield tells #BBCBreakfast why he's running 7 ultra marathons in 7 days to raise money for #mnd

Kevin Sinfield is starting his fourth challenge to raise money to support people affected by motor neurone disease. The 7 in 7 in 7 Challenge will see him run 7 ultra-marathons in 7 days in 7 cities. He sent a message to 3 people living with MND bbc.co.uk/news/uk-englan…

#Enhertu for HER2-low breast cancer is a drug that offers women like Tracy the life-changing hope of more time to live. But they're facing an agonising wait to see if they can access it on the NHS. NHS England and Daiichi Sankyo UK must urgently agree a deal to make it available.

"Knowing this treatment exists but is out of reach is so cruel." Thank you very much to nadia sawalha for sharing this personal story of her dear friend Hannah.

As chair of Health and Social Care Committee I am doing all I can to support this campaign. Will be raising again with members at our meeting next Tuesday.

Fantastic news! Talazoparib (Talzenna) has been approved for use on the NHS in England - the first targeted treatment for certain people with locally advanced or secondary breast cancer who’ve inherited an altered BRCA gene.

BREAKING - #EnhertuEmergency: Thousands of women with incurable HER2-low secondary breast cancer have just been denied access to the drug Enhertu. It’s a drug that would’ve given them the hope of more time to live. But it has been rejected for use on the NHS in England.

I've joined with Breast Cancer Now to call on NICE, NHS England, AstraZenecaUK and Daiichi Sankyo UK to make the life-extending drug, Enhertu available on the NHS. Will you join me? Sign the petition #EnhertuEmergency action.breastcancernow.org/enhertu-emerge…

Thank you for 38,000 signatures in 1 day! Help us keep up the momentum around our #EnhertuEmergency petition! action.breastcancernow.org/enhertu-emerge…

📣 An incredible 65,000 signatures in just over 48 hours - our fastest-growing petition ever! NICE, NHS England, Daiichi Sankyo UK, and AstraZenecaUK must listen and take action. Please keep signing and sharing widely. action.breastcancernow.org/enhertu-emerge…

“It won’t only affect those of us living with secondary breast cancer now, but also those that will develop it in the future." - Tracy Sign our petition – help make the drug Enhertu available on the NHS to the women who need it. action.breastcancernow.org/enhertu-emerge…

Kevin Sinfield pays tribute to his friend Rob Burrow after the former Leeds Rhinos side passed away on Sunday

Some of the incredible women campaigning for access to the drug #Enhertu, have written to NHS England, @daiichisankyouk, AstraZenecaUK and NICE, asking them to do everything they can to make it available on the NHS.